Company Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors.
Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies.
Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Raquel Izumi |
Contact Details
Address: 260 Sheridan Avenue, Suite 400 Palo Alto, California 94306 United States | |
| Phone | 650 800 6676 |
| Website | vincerx.com |
Stock Details
| Ticker Symbol | VINC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001796129 |
| CUSIP Number | 92731L106 |
| ISIN Number | US92731L1061 |
| Employer ID | 83-3197402 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, Acting Chief Executive Officer, Secretary and Director |
| Dr. Ahmed M. Hamdy M.D. | Co-Founder and Chairman |
| Tom C. Thomas J.D. | Founder, General Counsel and Chief Legal Officer |
| Dr. John C. Byrd M.D. | Founder and Chairman of Scientific Advisory Board |
| Kevin Haas | Acting Chief Financial Officer, Vice President of Finance and Corporate Controller |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Gabriela Jairala | Vice President of Investor Relations and Corporate Communications and Chief of Staff |
| Karen Quarford M.B.A. | Vice President of Quality Operations and Compliance |
| Melissa Merrick SPHR | Senior Director of People and Culture and Head of Human Resource |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |